Blockbuster Potential in Three Companies with Near Term FDA Review Dates

Biotech, medical and pharmaceutical stocks have a few things in common. First, is the potential for huge profits, generated from new technology platforms or new drugs. Many of these companies have lower share prices that make investor entry affordable. The company may have no revenue, high expenses or other factors holding the share price down while they wait for their pipeline drugs to develop and come to market. Another thing many of these companies have in common is the Federal Drug Administration. Investors who follows these types of companies know that fortunes can be made or lost based on an FDA decision, making the share price soar or collapse.

Keeping track of emerging drugs and technologies can be a full time job and many investors just don’t have the time. Traders News Source ( presents reports on three of these companies today, with near term FDA reviews, which could provide large catalysts.

Get These Three Tickers and Read Full Company Reports Here- READ MORE